-
1
-
-
0030895312
-
Protease inhibitors in patients with HIV disease: Clinically important pharmacokinetic considerations
-
▶1. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997;32:194-209.
-
(1997)
Clin Pharmacokinet
, vol.32
, pp. 194-209
-
-
Barry, M.1
Gibbons, S.2
Back, D.3
Mulcahy, F.4
-
2
-
-
0031024382
-
Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: Potential contribution to high first-pass metabolism
-
Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 1997;25:256-266
-
(1997)
Drug Metab Dispos
, vol.25
, pp. 256-266
-
-
Fitzsimmons, M.E.1
Collins, J.M.2
-
3
-
-
0030852009
-
Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir
-
▶3. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997;44:190-194
-
(1997)
Br J Clin Pharmacol
, vol.44
, pp. 190-194
-
-
Eagling, V.A.1
Back, D.J.2
Barry, M.G.3
-
5
-
-
0031751330
-
Clinical pharmacokinetics and interactions with other anti-HIV agents
-
▶5. Hsu A, Granneman GR, Bertz RJ. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998;35:275-291
-
(1998)
Clin Pharmacokinet
, vol.35
, pp. 275-291
-
-
Hsu, A.1
Granneman, G.R.2
Bertz, R.J.3
-
7
-
-
70349683330
-
Effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam
-
Frye R, Bertz RJ, Granneman GR, et al. Effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam. Presented at the 37th interscience conference on antimicrobial agents and chemotherapy, Toronto, Ontario, Canada, September 28-October 1, 1997.
-
37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 28-October 1, 1997
-
-
Frye, R.1
Bertz, R.J.2
Granneman, G.R.3
-
8
-
-
0021812823
-
Midazolam, the first water-soluble benzodiazepine: Pharmacology, pharmacokinetics, and efficacy in insomnia and anesthesia
-
Kanto JH. Midazolam, the first water-soluble benzodiazepine: pharmacology, pharmacokinetics, and efficacy in insomnia and anesthesia. Pharmacotherapy 1985;5:138-155
-
(1985)
Pharmacotherapy
, vol.5
, pp. 138-155
-
-
Kanto, J.H.1
-
9
-
-
0028114619
-
Use of midazolam as a human cytochrome P450 3A probe. I. in vitro-in vivo correlations in liver transplant patients
-
Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe. I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-556
-
(1994)
J Pharmacol Exp Ther
, vol.271
, pp. 549-556
-
-
Thummel, K.E.1
Shen, D.D.2
Podoll, T.D.3
-
10
-
-
0020529025
-
Relationship between plasma concentration and effect of midazolam after oral and intravenous administration
-
Crevoisier C, Ziegler WH, Eckert M, Heizmann P. Relationship between plasma concentration and effect of midazolam after oral and intravenous administration. Br J Clin Pharmacol 1983;16(suppl 1):S51-61.
-
(1983)
Br J Clin Pharmacol
, vol.16
, Issue.SUPPL. 1
-
-
Crevoisier, C.1
Ziegler, W.H.2
Eckert, M.3
Heizmann, P.4
-
11
-
-
0026611310
-
Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers
-
Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992;51:715-728
-
(1992)
Clin Pharmacol Ther
, vol.51
, pp. 715-728
-
-
Mandema, J.W.1
Tuk, B.2
Van Steveninck, A.L.3
Breimer, D.D.4
Cohen, A.F.5
Danhof, M.6
-
12
-
-
0028234586
-
Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily
-
▶12. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994;47:1643-1653
-
(1994)
Biochem Pharmacol
, vol.47
, pp. 1643-1653
-
-
Gorski, J.C.1
Hall, S.D.2
Jones, D.R.3
VandenBranden, M.4
Wrighton, S.A.5
-
13
-
-
0004061014
-
-
New York, NY: Marcel Dekker, Inc.
-
Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed., New York, NY: Marcel Dekker, Inc., 1982.
-
(1982)
Pharmacokinetics, 2nd Ed.
-
-
Gibaldi, M.1
Perrier, D.2
-
14
-
-
59749096917
-
Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir
-
▶14. Kaeser B, Zhang X, Zandt H, et al. Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir. Antimicrob Agents Chemother 2009;53:609-614
-
(2009)
Antimicrob Agents Chemother
, vol.53
, pp. 609-614
-
-
Kaeser, B.1
Zhang, X.2
Zandt, H.3
-
15
-
-
0032807936
-
Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam
-
▶15. Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther 1999;66:33-39
-
(1999)
Clin Pharmacol Ther
, vol.66
, pp. 33-39
-
-
Palkama, V.J.1
Ahonen, J.2
Neuvonen, P.J.3
Olkkola, K.T.4
-
16
-
-
57749197592
-
Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure
-
▶16. Mathias AA, West S, Hui J, Kearney BP. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009;85:64-70.
-
(2009)
Clin Pharmacol Ther
, vol.85
, pp. 64-70
-
-
Mathias, A.A.1
West, S.2
Hui, J.3
Kearney, B.P.4
-
17
-
-
0029738490
-
First-pass metabolism of midazolam by the human intestine
-
▶17. Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996;60:14-24.
-
(1996)
Clin Pharmacol Ther
, vol.60
, pp. 14-24
-
-
Paine, M.F.1
Shen, D.D.2
Kunze, K.L.3
-
18
-
-
33745433348
-
Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers
-
Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006;42:52-60.
-
(2006)
J Acquir Immune Defic Syndr
, vol.42
, pp. 52-60
-
-
Yeh, R.F.1
Gaver, V.E.2
Patterson, K.B.3
-
20
-
-
57649136624
-
Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis
-
▶20. Knox TA, Oleson L, von Moltke LL, Kaufman RC, Wanke CA, Greenblatt DJ. Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. J Acquir Immune Defic Syndr 2008;49:358-368
-
(2008)
J Acquir Immune Defic Syndr
, vol.49
, pp. 358-368
-
-
Knox, T.A.1
Oleson, L.2
Von Moltke, L.L.3
Kaufman, R.C.4
Wanke, C.A.5
Greenblatt, D.J.6
-
21
-
-
0032700543
-
Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole
-
▶21. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 1999;66:461-471
-
(1999)
Clin Pharmacol Ther
, vol.66
, pp. 461-471
-
-
Tsunoda, S.M.1
Velez, R.L.2
Von Moltke, L.L.3
Greenblatt, D.J.4
|